MX2009004765A - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf). - Google Patents

Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf).

Info

Publication number
MX2009004765A
MX2009004765A MX2009004765A MX2009004765A MX2009004765A MX 2009004765 A MX2009004765 A MX 2009004765A MX 2009004765 A MX2009004765 A MX 2009004765A MX 2009004765 A MX2009004765 A MX 2009004765A MX 2009004765 A MX2009004765 A MX 2009004765A
Authority
MX
Mexico
Prior art keywords
vegf
human
molecules
growth factor
vascular endothelial
Prior art date
Application number
MX2009004765A
Other languages
English (en)
Inventor
Santiago Glay Chinea
Cowley Jorge Victor Gavilondo
Cruz Osmany Guirola
Vispo Nelson Francisco Santiago
Ordas Humberto Lamdan
Avila Marta Ayala
Dorantes Gertrudis Rojas
Diaz Yanelys Morena
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2009004765A publication Critical patent/MX2009004765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La invención se refiere a moléculas polipeptídicas recombinantes relacionadas con anticuerpos, que reconocen específicamente el factor de crecimiento de endotelio vascular-A (VEGF-A) humano, e interfieren con sus efectos estimulatorios in vitro, y pro-angiogénicos in vivo; dichas moléculas polipeptídicas recombinantes son capaces de afectar la proliferación de células endoteliales humanas in vitro, la angiogénesis subcutánea en ratones inducida por tapones de matrigel que contienen VEGF-A, y el crecimiento de tumores humanos transplantados a ratones desnudos; varias de estas moléculas previenen la neovascularización coroidea en un modelo experimental en primates no humanos; estas moléculas pueden emplearse para la inmunoterapia pasiva de entidades patológicas cuyo curso se asocia al aumento de la vasculatura, tales como la degeneración macular asociada a la edad (variante húmeda), el cáncer y sus metástasis, los glaucomas neovasculares, la retinopatía diabética y del recién nacido, los procesos inflamatorios agudos y crónicos, enfermedades infecciosas, enfermedades autoinmunes, el rechazo al transplante de órganos, los hemangiomas y los angiofibromas, entre otros.
MX2009004765A 2006-11-01 2007-10-30 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf). MX2009004765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060208A CU23636A1 (es) 2006-11-01 2006-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
PCT/CU2007/000019 WO2008052489A1 (es) 2006-11-01 2007-10-30 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)

Publications (1)

Publication Number Publication Date
MX2009004765A true MX2009004765A (es) 2009-06-05

Family

ID=39148565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004765A MX2009004765A (es) 2006-11-01 2007-10-30 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf).

Country Status (15)

Country Link
US (1) US20100151566A1 (es)
EP (1) EP2093236A1 (es)
JP (1) JP2010508033A (es)
KR (1) KR20090078363A (es)
CN (1) CN101573379A (es)
AR (1) AR063448A1 (es)
AU (1) AU2007315484A1 (es)
BR (1) BRPI0717971A2 (es)
CA (1) CA2667594A1 (es)
CO (1) CO6341480A2 (es)
CU (1) CU23636A1 (es)
MX (1) MX2009004765A (es)
RU (1) RU2009120536A (es)
WO (1) WO2008052489A1 (es)
ZA (1) ZA200903017B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
CU23895B1 (es) * 2010-12-28 2013-05-31 Biorec Sa Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
CN103012588A (zh) * 2011-09-23 2013-04-03 武汉吉天朋生物科技发展有限公司 利用具有中和VEGFA生物学活性的McAb应用于肿瘤的靶向治疗
CN104073502B (zh) * 2013-03-26 2016-08-24 华东师范大学 人脑钠肽的中和性基因工程抗体3c1及其制备方法和应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CL2014002941A1 (es) * 2014-10-30 2015-04-06 Univ Concepcion Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf)
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CU20210101A7 (es) 2021-12-15 2023-07-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen a factores de crecimiento proangiogénicos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK0438200T3 (da) 1990-01-16 2002-11-11 Ct Ingenieria Genetica Biotech Fremgangsmåde til ekspression af heterologe gener i gæren Pichia pastoris, ekspressionsvektorer og transformerede mikroorganismer
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
RU2009120536A (ru) 2010-12-10
BRPI0717971A2 (pt) 2013-11-12
CN101573379A (zh) 2009-11-04
CO6341480A2 (es) 2011-11-21
JP2010508033A (ja) 2010-03-18
WO2008052489A1 (es) 2008-05-08
KR20090078363A (ko) 2009-07-17
AR063448A1 (es) 2009-01-28
US20100151566A1 (en) 2010-06-17
ZA200903017B (en) 2010-03-31
AU2007315484A1 (en) 2008-05-08
WO2008052489A8 (es) 2009-07-23
CU23636A1 (es) 2011-03-21
EP2093236A1 (en) 2009-08-26
CA2667594A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
MX2009004765A (es) Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf).
Guan et al. Mesenchymal stem cells in the tumor microenvironment
Kwon et al. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients
Kasaai et al. Erythro-myeloid progenitors can differentiate from endothelial cells and modulate embryonic vascular remodeling
BR112013019105A2 (pt) nanopartículas carregadas com medicamento antitumoral quimioterapêutico
WO2012094679A3 (en) Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
UA98841U (en) Smoking article (1)
WO2011002721A8 (en) Non-human mammal model of human hematopoietic cancer
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
MX355042B (es) Metodos para aumentar adipositos termogenicos.
EA200971056A1 (ru) ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx®
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
Liu et al. Downregulation of FGL 2/prothrombinase delays HCCLM 6 xenograft tumour growth and decreases tumour angiogenesis
EA201491578A1 (ru) Подкожное введение идуронат-2-сульфатазы
IN2014DN08199A (es)
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
Cui et al. Ambient fine particulate matter suppresses in vivo proliferation of bone marrow stem cells through reactive oxygen species formation
Scarlett Contribution of bone marrow derived cells to the pancreatic tumor microenvironment
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
Cao et al. Therapeutic effects of hepatocyte growth factor-overexpressing dental pulp stem cells on liver cirrhosis in a rat model
Solly et al. The role of miR-181c in mechanisms of diabetes-impaired angiogenesis: an emerging therapeutic target for diabetic vascular complications
WO2010121122A3 (en) Biomechanical induction of hematopoiesis
MX2015013092A (es) Modificación y nuevas composiciones de proteínas secretoglobinas de humano.
Hu et al. Mir-218 contributes to the transformation of 5-Aza/GF induced umbilical cord mesenchymal stem cells into hematopoietic cells through the MITF pathway